Literature DB >> 3186580

Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy.

J K Onwubalili1.   

Abstract

Two patients with nephrotic syndrome developed fatal fulminant hepatitis B following withdrawal of prednisolone or cyclophosphamide. Immunosuppressive therapy probably enhanced hepatitis B virus (HBV) replication and widespread infection of hepatocytes; its withdrawal permitted a return of immune competence resulting in massive destruction of infected hepatocytes. Prior screening of all patients for hepatitis B surface antigen, gradual withdrawal of immunosuppressive drugs with careful monitoring, and prompt intervention with corticosteroids at the first clinical or biochemical signs of liver cell damage may prevent this complication.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3186580      PMCID: PMC2428506          DOI: 10.1136/pgmj.64.750.325

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  10 in total

1.  Treatment of the nephrotic syndrome with nitrogen mustard.

Authors:  R D TAYLOR; A C CORCORAN; I H PAGE
Journal:  J Lab Clin Med       Date:  1950-12

2.  The nephrotic syndrome in Uganda and its association with quartan malaria.

Authors:  J W Kibukamusoke; M S Hutt; N E Wilks
Journal:  Q J Med       Date:  1967-07

3.  Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children.

Authors:  W J Brzosko; K Krawczyński; T Nazarewicz; M Morzycka; A Nowoslawski
Journal:  Lancet       Date:  1974-08-31       Impact factor: 79.321

4.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

5.  HBsaG in renal disease.

Authors:  J Nagy; G Bajtai; H Brasch; T Süle; M Ambrus; G Deák; A Hamori
Journal:  Lancet       Date:  1978-08-05       Impact factor: 79.321

6.  Hepatitis-B virus infection in children and adults in Northern Nigeria: a preliminary survey.

Authors:  Y M Fakunle; M B Abdurrahman; H C Whittle
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

7.  The role of hepatitis B surface antigen (HBsAg) in acute glomerulonephritis in adults.

Authors:  E N Obineche; C Awunor-Renner
Journal:  East Afr Med J       Date:  1981-05

8.  Letter: Subacute and chronic active hepatitis after withdrawal of chemotherapy.

Authors:  J R Wands
Journal:  Lancet       Date:  1975-11-15       Impact factor: 79.321

9.  Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier.

Authors:  S N Thung; M A Gerber; F Klion; H Gilbert
Journal:  Arch Intern Med       Date:  1985-07

10.  Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Authors:  R M Galbraith; A L Eddleston; R Williams; A J Zuckerman
Journal:  Lancet       Date:  1975-09-20       Impact factor: 79.321

  10 in total
  5 in total

1.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

Review 2.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 3.  Dangers of immunosuppressive therapy in hepatitis B virus carriers.

Authors:  E Lueg; J Heathcote
Journal:  CMAJ       Date:  1992-10-15       Impact factor: 8.262

Review 4.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

Review 5.  Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management.

Authors:  Alessandra Zannella; Massimo Marignani; Paola Begini
Journal:  Viruses       Date:  2019-09-14       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.